Avastin® Herceptin® Breast cancer HER 2+ About Herceptin® Herceptin® development Administration Efficacy Adjunvant efficacy Neoadjuvant efficacy Metastasic breast cancer efficacy First line H0648g (pivotal trial) M77001 Trial Subsequent lines of therapy Hormone receptor co-positive tumours Safety Cardiac safety Dosage Mabthera® Tarceva® Xeloda®

Home/EN/Product information/Herceptin®/Efficacy/Metastasic breast cancer efficacy/M77001 Trial M77001 Trial  M77001 trial A Phase III, randomised, open-label trial comparing taxane therapy with or without Herceptin as first-line treatment in HER2-positive MBC.

Privacy Policy | Legal Statement The information on this Web site is intended only for visitors from Aruba, Bahamas, Barbados, Bermuda, Curacao, Jamaica, St. Maarten, St. Lucia and Trinidad & Tobago All rights reserved © 2008 F. Hoffmann-La Roche Ltd.